GoodRx Holdings (GDRX, Health Care Technology) Stock Valuation & Fair Value Fairly valued
GoodRx Holdings (GDRX, Health Care Technology) trades at a blended P/E of 10.8, about 70% below its historical normal valuation, with a forward growth estimate of 12.9% and a PEG of 0.83. Analysts' one-year estimates have been hit 40% of the time. Priced at its historical normal P/E of 35.8 on the same blended earnings, the 2026-09-18 close of $3.38 corresponds to about $11.30 a share. This is a valuation reference, not a price target.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been fairly valued since 2026-07-31.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Frequently asked questions
Is GoodRx Holdings stock overvalued?
At a blended P/E of 10.8 versus its historical normal P/E of 35.8, GoodRx Holdings trades about 70% below its typical valuation, with a PEG of 0.83 on 12.9% forward growth. tickerseer currently rates it fairly valued.
What is GoodRx Holdings's fair value and PEG?
GoodRx Holdings trades at a blended P/E of 10.8 against a historical normal P/E of 35.8, a PEG of 0.83, and a forward growth estimate of 12.9%. Priced at its historical normal P/E of 35.8 on the same blended earnings, the 2026-09-18 close of $3.38 corresponds to about $11.30 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of GoodRx Holdings changed?
tickerseer's rating has been fairly valued since 2026-07-31.
Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.